Innate Pharma Stock Investor Sentiment

IPHA Stock  USD 1.79  0.03  1.70%   
About 55% of Innate Pharma's investors are presently thinking to get in. The analysis of overall sentiment of trading Innate Pharma stock suggests that some investors are interested at this time. The current market sentiment, together with Innate Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Innate Pharma stock news signals to limit their universe of possible portfolio assets.
  
few days ago at news.google.com         
Innate Pharma Begins Phase 1 Study of New Cancer Therapy - TipRanks
Google News at Macroaxis
over a week ago at businesswire.com         
Innate Pharma annonce lorganisation dune confrence destine aux analystes et investisseurs pour prsen...
businesswire News
over two weeks ago at businesswire.com         
Nouveau nombre dactions et de droits de vote dInnate Pharma au 31 dcembre 2024
businesswire News
over two weeks ago at businesswire.com         
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
businesswire News
over two weeks ago at businesswire.com         
Innate Pharma Announces Transformative Strategy to Accelerate Growth
businesswire News
over two weeks ago at businesswire.com         
Innate Pharma annonce une stratgie de transformation pour acclrer sa croissance
businesswire News
over a month ago at news.google.com         
Innate Pharma SAs Innovations Spotlighted at ASH 2024 - MSN
Google News at Macroaxis
over a month ago at businesswire.com         
Innate Pharma annonce sa participation a la 43me J.P. Morgan Healthcare Conference
businesswire News
over a month ago at businesswire.com         
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
businesswire News
over a month ago at news.google.com         
Innate Pharma Cyclically Adjusted PB Ratio 0.85 - GuruFocus.com
Google News at Macroaxis
over a month ago at businesswire.com         
Innate Pharma prsente lASH 2024 des donnes de ltude de Phase 2 TELLOMAK sur lamlioration de la quali...
businesswire News
over a month ago at businesswire.com         
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLO...
businesswire News
over a month ago at businesswire.com         
Innate Pharma and the Institute for Follicular Lymphoma Innovation Announce up to 7.9M Investment Fr...
businesswire News
over a month ago at businesswire.com         
Innate Pharma et lInstitut dInnovation pour le Lymphome Folliculaire annoncent un investissement jus...
businesswire News
over a month ago at businesswire.com         
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
businesswire News
Far too much social signal, news, headlines, and media speculation about Innate Pharma that are available to investors today. That information is available publicly through Innate media outlets and privately through word of mouth or via Innate internal channels. However, regardless of the origin, that massive amount of Innate data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Innate Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Innate Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Innate Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Innate Pharma alpha.

Innate Pharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Innate Stock analysis

When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity